Adamas Pharmaceuticals, Inc.
(NASDAQ : ADMS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
-2.35%165.900.4%$266.82m
VRXValeant Pharmaceuticals International, Inc.
-0.36%21.9514.1%$212.65m
PRGOPerrigo Co. Plc
-0.42%75.656.7%$103.44m
JAZZJazz Pharmaceuticals Plc
-0.66%165.992.2%$88.61m
PTLAPortola Pharmaceuticals, Inc.
-2.03%39.407.7%$77.02m
GWPHGW Pharmaceuticals PLC Sponsored ADR
3.87%157.697.6%$68.91m
SAGESAGE Therapeutics, Inc.
-4.31%157.299.6%$61.69m
MNKMallinckrodt Plc
0.87%16.2521.1%$57.48m
SUPNSupernus Pharmaceuticals, Inc.
-0.18%54.456.3%$48.02m
PBHPrestige Brands Holdings, Inc.
1.60%33.703.8%$39.62m
UTHRUnited Therapeutics Corporation
0.62%105.7314.4%$38.67m
ICPTIntercept Pharmaceuticals, Inc.
-0.37%69.7321.8%$32.24m
CTLTCatalent Inc
-1.87%39.332.6%$31.61m
HZNPHorizon Pharma plc
1.72%15.367.5%$30.60m
ENDPEndo International Plc
6.60%6.348.9%$29.71m

Company Profile

Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products includes ADS-5012, ADS-4101, and Namenda XR. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients with Parkinson's disease. The ADS-401 treats partial onset seizures in patients with epilepsy. The Namenda XR is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.